Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70098 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Cori Campbell und 30 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Oxford Biomedical Research Centre, Oxford, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC), National Institute for Health and Care Research, University College London.
Abstract (Originalsprache)
Nucleos/tide analogue (NA) drugs are used for long‐term treatment of chronic hepatitis B virus (HBV) infection, with treatment eligibility criteria changing rapidly amidst globally evolving clinical guidelines. We aimed to quantify the prescription of NA drugs to date, and to undertake a preliminary assessment of the impact of relaxing treatment eligibility thresholds, leveraging a unique large real‐world secondary care dataset. We assimilated longitudinal clinical data, collected between February 1997 and April 2023 from adults with chronic HBV infection from six centres in England through the UK NIHR Health Informatics Collaborative (HIC) Viral Hepatitis and Liver Disease theme. We describe factors currently associated with the receipt of NA treatment and determine the proportion of the population who would become treatment eligible as thresholds change. Across 7558 adults with a mean follow‐up of 4.0 years (SD 3.9), NA treatment was prescribed in 2014/7558 (26.6%), and as expected according to guidelines at the time, was associated with HBV e‐antigen (HBeAg) positivity and alanine transferase (ALT) above the upper limit of normal (> ULN). Treatment was more likely in males, older adults, in Asian and Other ethnicities (compared to White), and less likely in socioeconomically deprived individuals. The proportion of treatment‐eligible individuals was 32.3% based on 2 records of ALT > ULN over 6–12 months, 41.7% based on ALT > ULN and viral load (VL) > 2000 IU/mL, and 95.1% based on detectable VL and either ALT > ULN or age > 30 years. Evolving clinical guidelines will lead to substantial increases in the proportion of individuals living with HBV who are eligible for treatment, underlining the need for services to adapt rapidly to the changing clinical environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR Oxford Biomedical Research Centre, Oxford, UK.
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
- Tropical Infectious Diseases Unit, Royal Liverpool Hospital, Liverpool University Hospitals NHS Trust, Liverpool, UK.
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- iCARE Secure Data Environment, NIHR Imperial Biomedical Research Centre, Imperial College Healthcare NHS Trust, London, UK.
ORCID-Profile: Cori Campbell, Tingyan Wang, Alexander J Stockdale, Stacy Todd, Jakub Jaworski, Ben Glampson, Dimitri Papadimitriou, Erik Mayer, Hizni Salih, Gail Roadknight, Stephanie Little, Kinga A Várnai, Louise English, Kerrie Woods, Jim Davies, Graham S Cooke, Eleni Nastouli, Salim I Khakoo, Ahmed M Elsharkawy, Eleanor Barnes, Philippa C Matthews
Förderung
- National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC)
- National Institute for Health and Care Research
- University College London
Zitieren
APA
Campbell, C., Wang, T., Stockdale, A. J., Todd, S., Jaworski, J., Glampson, B., Papadimitriou, D., Mayer, E., Salih, H., Roadknight, G., Little, S., Noble, T., Várnai, K. A., Davis, C., Heinson, A. I., George, M., Borca, F., Roberts, T., Ribeyre, B. B., …, & Matthews, P. C. (2025). Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70098
Vancouver
Campbell C, Wang T, Stockdale AJ, Todd S, Jaworski J, Glampson B, et al. Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70098
BibTeX
@article{Campbell2025,
author = {Campbell, Cori and Wang, Tingyan and Stockdale, Alexander J and Todd, Stacy and Jaworski, Jakub and Glampson, Ben and Papadimitriou, Dimitri and Mayer, Erik and Salih, Hizni and Roadknight, Gail and Little, Stephanie and Noble, Theresa and Várnai, Kinga A and Davis, Cai and Heinson, Ashley I and George, Michael and Borca, Florina and Roberts, Timothy and Ribeyre, Baptiste B and English, Louise and Zhu, Leilei and NIHR HIC Viral Hepatitis and Liver Disease Consortium, NIHR HIC Viral Hepatitis and Liver Disease Consortium and Woods, Kerrie and Davies, Jim and Cooke, Graham S and Nastouli, Eleni and Khakoo, Salim I and Gelson, William and Elsharkawy, Ahmed M and Barnes, Eleanor and Matthews, Philippa C},
title = {Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70098}
}
EUVIMED